173 related articles for article (PubMed ID: 9412659)
1. A pharmacodynamic study of morphine and its glucuronide metabolites after single morphine dosing in cancer patients with pain.
Hoffman M; Xu JC; Smith C; Fanelli C; Pascal V; Degaetano C; Meenan G; Lehrer M; Lesser M; Citron M
Cancer Invest; 1997; 15(6):542-7. PubMed ID: 9412659
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.
Andersen G; Sjøgren P; Hansen SH; Jensen NH; Christrup L
Eur J Pain; 2004 Jun; 8(3):263-71. PubMed ID: 15109977
[TBL] [Abstract][Full Text] [Related]
5. Relationship between plasma concentrations of morphine and its metabolites and pain in cancer patients.
Sakurada T; Takada S; Eguchi H; Izumi K; Satoh N; Ueda S
Pharm World Sci; 2010 Dec; 32(6):737-43. PubMed ID: 20730493
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers.
Lötsch J; Stockmann A; Kobal G; Brune K; Waibel R; Schmidt N; Geisslinger G
Clin Pharmacol Ther; 1996 Sep; 60(3):316-25. PubMed ID: 8841154
[TBL] [Abstract][Full Text] [Related]
7. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers.
Murthy BR; Pollack GM; Brouwer KL
J Clin Pharmacol; 2002 May; 42(5):569-76. PubMed ID: 12017351
[TBL] [Abstract][Full Text] [Related]
8. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
Wolff T; Samuelsson H; Hedner T
Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.
Oosten AW; Abrantes JA; Jönsson S; Matic M; van Schaik RHN; de Bruijn P; van der Rijt CCD; Mathijssen RHJ
Clin Pharmacokinet; 2017 Jul; 56(7):733-746. PubMed ID: 27815868
[TBL] [Abstract][Full Text] [Related]
10. Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery.
Dale O; Thoner J; Nilsen T; Tveita T; Borchgrevink PC; Klepstad P
Eur J Clin Pharmacol; 2007 Sep; 63(9):837-42. PubMed ID: 17619868
[TBL] [Abstract][Full Text] [Related]
11. The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.
Lasheen W; Walsh D; Mahmoud F; Sarhill N; Rivera N; Davis M; Lagman R; Legrand S
Palliat Med; 2010 Jan; 24(1):9-16. PubMed ID: 19910396
[TBL] [Abstract][Full Text] [Related]
12. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
Du X; Skopp G; Aderjan R
Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
[TBL] [Abstract][Full Text] [Related]
13. Interindividual variation in the ratio between plasma morphine and its metabolites in cancer patients.
Tateishi M; Ohashi K; Kobayashi K; Hashimoto T; Yamaguchi J; Fujioka H; Izawa K; Masada M
Int J Clin Pharmacol Res; 2003; 23(2-3):75-82. PubMed ID: 15018021
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences.
Romberg R; Olofsen E; Sarton E; den Hartigh J; Taschner PE; Dahan A
Anesthesiology; 2004 Jan; 100(1):120-33. PubMed ID: 14695733
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain.
Hunt A; Joel S; Dick G; Goldman A
J Pediatr; 1999 Jul; 135(1):47-55. PubMed ID: 10393603
[TBL] [Abstract][Full Text] [Related]
16. Morphine analgesia in cancer pain: role of the glucuronides.
Penson RT; Joel SP; Gloyne A; Clark S; Slevin ML
J Opioid Manag; 2005; 1(2):83-90. PubMed ID: 17319252
[TBL] [Abstract][Full Text] [Related]
17. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine.
Andersen G; Jensen NH; Christrup L; Hansen SH; Sjøgren P
Palliat Med; 2002 Mar; 16(2):107-14. PubMed ID: 11969141
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurement and integrated analysis of analgesia and respiration after an intravenous morphine infusion.
Dahan A; Romberg R; Teppema L; Sarton E; Bijl H; Olofsen E
Anesthesiology; 2004 Nov; 101(5):1201-9. PubMed ID: 15505457
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs.
KuKanich B; Lascelles BD; Papich MG
J Vet Pharmacol Ther; 2005 Aug; 28(4):371-6. PubMed ID: 16050817
[TBL] [Abstract][Full Text] [Related]
20. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function.
Portenoy RK; Thaler HT; Inturrisi CE; Friedlander-Klar H; Foley KM
Clin Pharmacol Ther; 1992 Apr; 51(4):422-31. PubMed ID: 1563212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
